Park, Keunchil
Mayo Clinic
The University of Texas MD Anderson Cancer Center
Citations 4
Plain language summary of PAPILLON: amivantamab plus chemotherapy in untreated EGFR -mutated non-small-cell lung cancer
Sabari, Joshua K. , Agrawal, Trishala, Zhou, Caicun , Girard, Nicolas , Mansfield, Aaron S. , Sanborn, Rachel E , Park, Keunchil
Future Oncology | July 16, 2024 | Volume: 20 | Issue: 32 | Pages: 2409-2421
First-in-human trial of microRNA cancer therapy with MRX34, a liposomal miR-34 mimic: Phase Ia expansion in patients with advanced solid tumors.
Beg, Muhammad Shaalan , Sachdev, Jasgit C. , Lim, Ho Yeong , Kim, Tae‐You, Becerra, Carlos, Bader, Andreas G. , Stoudemire, Jay, Smith, Susan, Kim, Sinil, Hong, David S. , Brenner, Andrew Jacob , Borad, Mitesh J. , Park, Keunchil , Smith, Susan, Kang, Yoon‐Koo
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS2597-TPS2597
MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: Final dose-escalation results from a first-in-human phase I trial of microRNA therapy.
Sachdev, Jasgit C. , Ejadi, Samuel, Kim, Tae‐You, Lim, Ho Yeong , Becerra, Carlos, Bader, Andreas G. , Stoudemire, Jay, Smith, Susan, Kim, Sinil, Beg, Muhammad Shaalan , Hong, David S. , Kang, Yoon‐Koo , Brenner, Andrew Jacob , Borad, Mitesh J. , Park, Keunchil , Smith, Susan
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 2508-2508
A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC.
Camidge, D. Ross , Demedts, Ingel , Grosch, Heidrun, Mercurio, Jean-Pierre Di , Molina, Julian R. , Bepler, Gerold , Lewanski, C., Wijayawardana, Sameera R. , Wang, Xuejing Aimee , Morán, Teresa , Mileham, Kathryn Finch , Juan, Óscar , Goldman, Jonathan W. , Park, Keunchil , Wallin, Johan Erik , Wacheck, Volker , Smit, Egbert F
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 9070-9070